# Major Recall Alert: STA - Fib 2, STA - Fibrinogen 5, STA - Liquid Anti-Xa 4, STA - Liquid Anti-Xa 8, STA Satellite, and STA Satellite Max Recalled Due to Contamination Risk
On **July 21, 2025**, a significant recall was announced involving **STA®-Fib 2, STA®-Fibrinogen 5, STA®-Liquid Anti-Xa 4 and 8, STA Satellite, and STA Satellite Max** products. The recall stems from contamination of **STA®-Liquid Anti-Xa** reagents identified during **internal testing**. This contamination occurs when **STA-Fibrinogen 5** tests are performed prior to **STA-Liquid Anti-Xa** tests for heparin monitoring.
Such errors can lead to an **underestimation of heparin levels**, potentially causing incorrect **heparin treatment adjustments** and, in severe cases, risking a **heparin overdose** for patients.
Keep reading to learn why this recall is critical and what you need to do next to stay safe.
## Why This Recall is Important
Monitoring heparin levels is crucial for patients undergoing treatment for clot prevention, particularly those on **UFH (unfractionated heparin)** or **LMWH (low molecular weight heparin)**. The safety issue arises from **cross-contamination** due to reagent carryover when certain STA test combinations are performed sequentially.
The **underestimation of heparin levels** can lead to incorrect changes in dosage, which could result in **overdosing**. Overdose risks include severe complications such as **internal bleeding** or other life-threatening health events. Immediate action is required to protect patient safety.
## Details of the Recall
Here are the key details about the affected products and contamination issue:
- **Category**: Medical Testing Reagents (Heparin Monitoring)
- **Affected Products**:
- STA®-Fib 2
- STA®-Fibrinogen 5
- STA®-Liquid Anti-Xa 4
- STA®-Liquid Anti-Xa 8
- STA Satellite
- STA Satellite Max
- **Issue**: Cross-contamination during testing results in underestimating heparin levels, leading to potential treatment errors.
- **Recall Start Date**: **July 21, 2025**
- **Reason for Recall**: **Contamination of STA®-Liquid Anti-Xa reagents by STA®-Fibrinogen reagents.**
For more details regarding this recall, refer to the official announcement from the **Canadian Recall Database** [here](https://recalls-rappels.canada.ca/en/alert-recall/sta-liquid-anti-xa).
## What You Should Do
If you are a healthcare provider using these products, follow these steps immediately:
1. **Verify affected products**: Check inventories for items listed in this recall.
2. **Stop using recalled products**: Discontinue using the affected STA reagents and devices immediately.
3. **Contact the manufacturer**: Reach out to your distributor or **STA by Stago** for replacements or further guidance.
4. **Report adverse events**: If you suspect any adverse effects related to these products, report them to **Health Canada** and the manufacturer right away.
Patients undergoing heparin treatment should contact their healthcare provider to ensure their tests are accurate and their treatment remains safe.
## Stay Safe – Get Instant Recall Alerts
To stay updated on this and other critical recalls, download our **Recall Alerts App** today. With real-time notifications on product recalls, safety alerts, and actionable guidance, you can safeguard your health and well-being proactively.
[Download the Recall Alerts App](#) and keep yourself and your loved ones informed about the latest safety information!
## Final Thoughts
This recall highlights the importance of precision in medical testing, particularly for life-saving treatments like heparin monitoring. Whether you're a healthcare provider or a patient, it's critical to take swift action and stay informed about these developments.
For more information about the contamination and recall process, visit the **official recall page by Health Canada** [here](https://recalls-rappels.canada.ca/en/alert-recall/sta-liquid-anti-xa). Stay alert, follow the recommended safety measures, and prioritize your health.